Alveolar rhabdomyosarcoma of cervix: A case report

宫颈肺泡状横纹肌肉瘤:病例报告

阅读:1

Abstract

RATIONALE: Alveolar rhabdomyosarcoma (ARMS) is a rare and highly aggressive malignant soft tissue tumor. ARMS is associated with a poor prognosis, especially in adults, occurring in the uterine cervix infrequently. To date, only 6 cases have been reported in the literature. We discuss the challenges in diagnosing and managing cervical ARMS and highlights the need for ongoing research into optimal treatment strategies for this malignancy. PATIENT CONCERNS: A 51-year-old female was diagnosed with advanced-stage ARMS. Positron emission tomography and computed tomography scans indicated a high metabolism mass in the uterus region, along with multiple lymph nodes enlargement in the pelvic, para-aorta and mediastinal regions. Cervical biopsy and segmental curettage revealed a small cell malignant tumor with poor differentiation. Histological and immunohistochemical examination confirmed ARMS. DIAGNOSES: The final diagnosis was cervical ARMS, staged IV according to the Intergroup Rhabdomyosarcoma Studies Group based on the imaging and histology results. INTERVENTIONS: The patient underwent radical hysterectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy, and para-aortic lymphadenectomy. Postoperatively, the patient received a series of chemotherapy regimens including VAC† (vincristine, epirubicin, cyclophosphamide), EP (etoposide and cisplatin), VIP (etoposide, ifosfamide, cisplatin), gemcitabine and bevacizumab, gemcitabine and docetaxel, pertuzumab and lenvatinib and radiotherapy. CONCLUSION: ARMS has low incidence with unique clinical pathological characteristics. The biological behavior is more aggressive and the prognosis is worse in ARMS. Further research is necessary to refine treatment protocols and improve survival rates for this aggressive tumor.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。